Biondi-Zoccai Giuseppe, Wu Yangfeng, Serrano Carlos V, Frati Giacomo, Agostoni Pierfrancesco, Abbate Antonio
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.
School of Public Health, Peking University, Beijing, PR China.
Int J Cardiol. 2015 Mar 1;182:148-54. doi: 10.1016/j.ijcard.2014.12.091. Epub 2014 Dec 27.
Despite momentous breakthroughs in unraveling the pathophysiology of many chronic conditions and developing novel therapeutic agents, everyday clinical practice is still fraught with inadequate or inappropriate use of treatments with proven benefits. Aspirin is a paradigmatic example, as it is used for the primary and secondary prevention of cardiovascular disease and appears to have a beneficial impact on cancer risk. Yet, underuse, non-compliance or cessation of aspirin are not uncommon, may have an important clinical impact, and are not aggressively prevented or managed. Increasing the awareness of the extent and impact of aspirin underuse, non-compliance or cessation, and intensifying efforts at preventing them are worthy goals likely to yield significant benefits on cardiovascular morbidity and mortality worldwide, and possibly also on cancer outcomes.
尽管在揭示许多慢性病的病理生理学以及开发新型治疗药物方面取得了重大突破，但日常临床实践中仍充斥着对已证实有益的治疗方法使用不足或不当的情况。阿司匹林就是一个典型例子，它用于心血管疾病的一级和二级预防，并且似乎对癌症风险有有益影响。然而，阿司匹林的使用不足、不依从或停药情况并不罕见，可能会产生重要的临床影响，而且没有得到积极的预防或处理。提高对阿司匹林使用不足、不依从或停药的程度及影响的认识，并加大预防力度，是有望在全球心血管发病率和死亡率方面产生显著益处、甚至可能对癌症治疗结果也有益处的重要目标。
